Analysis of local control in patients receiving IMRT for resected pancreatic cancers.

Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
International journal of radiation oncology, biology, physics (Impact Factor: 4.18). 01/2012; 83(3):916-20. DOI: 10.1016/j.ijrobp.2011.08.026
Source: PubMed

ABSTRACT Intensity-modulated radiotherapy (IMRT) is increasingly incorporated into therapy for pancreatic cancer. A concern regarding this technique is the potential for geographic miss and decreased local control. We analyzed patterns of first failure among patients treated with IMRT for resected pancreatic cancer.
Seventy-one patients who underwent resection and adjuvant chemoradiation for pancreas cancer are included in this report. IMRT was used for all to a median dose of 50.4 Gy. Concurrent chemotherapy was 5-FU-based in 72% of patients and gemcitabine-based in 28%.
At median follow-up of 24 months, 49/71 patients (69%) had failed. The predominant failure pattern was distant metastases in 35/71 patients (49%). The most common site of metastases was the liver. Fourteen patients (19%) developed locoregional failure in the tumor bed alone in 5 patients, regional nodes in 4 patients, and concurrently with metastases in 5 patients. Median overall survival (OS) was 25 months. On univariate analysis, nodal status, margin status, postoperative CA 19-9 level, and weight loss during treatment were predictive for OS. On multivariate analysis, higher postoperative CA19-9 levels predicted for worse OS on a continuous basis (p < 0.01). A trend to worse OS was seen among patients with more weight loss during therapy (p = 0.06). Patients with positive nodes and positive margins also had significantly worse OS (HR for death 2.8, 95% CI 1.1-7.5; HR for death 2.6, 95% CI 1.1-6.2, respectively). Grade 3-4 nausea and vomiting was seen in 8% of patients. Late complication of small bowel obstruction occurred in 4 (6%) patients.
This is the first comprehensive report of patterns of failure among patients treated with adjuvant IMRT for pancreas cancer. IMRT was not associated with an increase in local recurrences in our cohort. These data support the use of IMRT in the recently activated EORTC/US Intergroup/RTOG 0848 adjuvant pancreas trial.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is the 10th most commonly diagnosed malignancy in the USA and the fourth most common cause of cancer-related death. Worldwide, the mortality incidence ratio approaches 98%. Although only 15–20% of patients present with resectable disease, there is international consensus that complete surgical resection (R0, i.e. grossly and microscopically negative margins) is a vital part of any curative treatment paradigm. Despite advances in surgical technique, peri-operative care, chemotherapy and radiation delivery techniques over the past two decades, 5 year overall survival rates for resected pancreatic cancer with modern therapies remain around 20–25%. There is level I evidence for adjuvant chemotherapy in fully resected pancreatic cancer, but randomised trials examining the role of adjuvant chemoradiotherapy to date do not provide clear support for radiation therapy in this setting. In addition, efforts to increase the proportion of long-term survivors have recently centred on increasing the resectability of locoregional disease by incorporating neoadjuvant treatment before definitive surgery. Post-hoc analysis of randomised data as well as retrospective reviews have shown that there are several independent prognostic factors that may have considerable impact on survival outcomes, complicating interpretation and comparison of historical data. There is considerable interest in adjuvant and neoadjuvant therapy, but there is significant controversy as to whether radiation is of value, especially in the adjuvant context. Herein, we explore the sources of those controversies.
    Clinical Oncology 09/2014; 26(9). DOI:10.1016/j.clon.2014.06.003 · 2.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the feasibility and efficacy of the combination of S-1 with gemcitabine followed by oral S-1 with concurrent radiotherapy (intensity modulated radiotherapy, IMRT) and maintenance therapy with S-1 for locally advanced pancreatic cancer.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In 2013, there will be an estimated 43,920 new cases and 37,390 deaths attributed to pancreatic cancer (PCA) in the USA [1]. At diagnosis, a large majority of patients with pancreatic cancer present with unresectable, locally advanced pancreatic cancer (LAPC), or metastatic disease. The prognosis of PCA, regardless of stage, is extremely poor, with a 1-year survival rate of 25 % and a 5-year survival rate of less than 5 % [2]. Validated early detection tests are unavailable, and screening imaging studies are not recommended. Therefore, patients are often not diagnosed until late in their disease, after their cancer has metastasized to other organs. Despite these horrible statistics, several innovations over the past few years provide hope for earlier detection and improved treatment options for patients with pancreatic cancer. In this issue of the Journal of Radiation Oncology, we will focus on how modern radiation therapy can be optimally integrated with chemotherapy, targeted therapi ...
    12/2013; 2(4):339-340. DOI:10.1007/s13566-013-0126-3